Carcinoma Breast: Correlation of Immunohistohemical Expression of Cyclin D1 and Its Correlation with Clinicopathological Parameters in Indian Patients at Tertiary Care Hospital

Mehta Ritu, Y. Rashmi
{"title":"Carcinoma Breast: Correlation of Immunohistohemical Expression of Cyclin D1 and Its Correlation with Clinicopathological Parameters in Indian Patients at Tertiary Care Hospital","authors":"Mehta Ritu, Y. Rashmi","doi":"10.23937/2643-4563/1710044","DOIUrl":null,"url":null,"abstract":"Aim: To study the prevalence of Cyclin D1 expression and its correlation with other clinicopathological parameters like age, tumor size, lymph node status, MBR grade, and expression of other immunohistochemical markers like ER, PR, Her 2 - neu, and Ki67. Material and Methods: Thirty cases diagnosed were included in the study. All the cases were subjected to routine histopathology along with IHC for ER PR, Her2-neu, Ki67, and Cyclin D1. Results: CylinD1 positivity was found in 70% of cases. Our study presented the following distribution of cases Luminal A, N = 6(20%), Luminal B, N = 5(16.7%), Triple-negative, N = 10(33.3%), Normal Like = 7(23.3%), Her2/neu enriched = 2(6.7%). N = 4(40%) of triple-negative molecular subtype were positive for the cyclin D1. Cyclin D1 positivity showed a strong correlation with ER, PR, Her2-neu, and Ki67 status. However, no other significant correlation was found with other factors. Conclusion: This study shows a positive correlation of CyclinD1 with many other prognostic markers like molecular subtype, ER, PR, Her2/neu, and Ki67. With the advent of CD4/6 inhibitors and their potential therapeutic effects in breast carcinoma, Cyclin D1 becomes a potential prognostic IHC marker and can aid in patient management in cases of breast carcinoma. Its association with other established markers and clinicopathological parameters needs to be researched thoroughly.","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of oncology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23937/2643-4563/1710044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To study the prevalence of Cyclin D1 expression and its correlation with other clinicopathological parameters like age, tumor size, lymph node status, MBR grade, and expression of other immunohistochemical markers like ER, PR, Her 2 - neu, and Ki67. Material and Methods: Thirty cases diagnosed were included in the study. All the cases were subjected to routine histopathology along with IHC for ER PR, Her2-neu, Ki67, and Cyclin D1. Results: CylinD1 positivity was found in 70% of cases. Our study presented the following distribution of cases Luminal A, N = 6(20%), Luminal B, N = 5(16.7%), Triple-negative, N = 10(33.3%), Normal Like = 7(23.3%), Her2/neu enriched = 2(6.7%). N = 4(40%) of triple-negative molecular subtype were positive for the cyclin D1. Cyclin D1 positivity showed a strong correlation with ER, PR, Her2-neu, and Ki67 status. However, no other significant correlation was found with other factors. Conclusion: This study shows a positive correlation of CyclinD1 with many other prognostic markers like molecular subtype, ER, PR, Her2/neu, and Ki67. With the advent of CD4/6 inhibitors and their potential therapeutic effects in breast carcinoma, Cyclin D1 becomes a potential prognostic IHC marker and can aid in patient management in cases of breast carcinoma. Its association with other established markers and clinicopathological parameters needs to be researched thoroughly.
乳腺癌:Cyclin D1免疫组织化学表达的相关性及其与三级医院印度患者临床病理参数的相关性
目的:研究细胞周期蛋白D1的表达率及其与其他临床病理参数的相关性,如年龄、肿瘤大小、淋巴结状态、MBR分级以及其他免疫组织化学标志物如ER、PR、Her 2-neu和Ki67的表达。材料和方法:30例确诊病例纳入研究。所有病例均接受常规组织病理学检查,同时进行ER PR、Her2-neu、Ki67和Cyclin D1的IHC检查。结果:CylinD1阳性率为70%。我们的研究显示,Luminal A,N=6(20%),Lumina B,N=5(16.7%),三阴性,N=10(33.3%),Normal Like=7(23.3%),Her2/neu富集=2(6.7%)。三阴性分子亚型中N=4(40%)的细胞周期蛋白D1呈阳性。Cyclin D1阳性与ER、PR、Her2-neu和Ki67状态密切相关。然而,没有发现与其他因素有其他显著相关性。结论:CyclinD1与许多其他预后标志物如分子亚型、ER、PR、Her2/neu和Ki67呈正相关。随着CD4/6抑制剂的出现及其在乳腺癌中的潜在治疗作用,细胞周期蛋白D1成为一种潜在的预后IHC标志物,并有助于乳腺癌患者的管理。它与其他已确定的标志物和临床病理参数的相关性需要深入研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信